CMND
Clearmind Medicine Inc. (CMND) Economic Moat Analysis (2026)
No material changes this month.
Intangible Assets
CMND shows no evident filing-backed intangible asset moat in the provided data, and the deeply negative TTM ROIC and ROCE indicate any brand or proprietary asset base is not translating into durable pricing power versus peers.
The absence of disclosed 5-year margin or return history in the supplied metrics prevents evidence of persistent premium economics, which weakens any claim of durable intangible advantage relative to peers.
No tier-1 evidence was provided for patents, licenses, regulatory exclusivity, or other protected assets, so the company appears to lack structural intangible barriers that would support retention or margin durability.
Compared with stronger peers that can defend pricing through recognized brands, IP, or regulated franchises, CMND’s current economics suggest its intangible position is not a meaningful source of competitive advantage.
Switching Costs
The provided metrics do not show customer lock-in, and the negative ROIC/ROCE imply customers are not paying enough to create durable switching friction versus peers.
A very negative cash conversion cycle does not by itself prove switching costs, and in this case it more likely reflects weak working-capital dynamics than embedded customer dependence.
No filing evidence was provided for long-term contracts, integration depth, or mission-critical workflows, so there is no basis to infer meaningful switching costs relative to peers.
Against peers with recurring revenue, embedded software, or regulated service relationships, CMND appears materially easier to replace, which limits retention and pricing power.
Network Effects
The supplied data contain no evidence of user growth loops, multi-sided participation, or data/network flywheels, so there is no observable network-effect moat.
Negative returns and zero asset turnover are inconsistent with a platform that becomes more valuable as usage expands, which argues against peer-leading network dynamics.
No tier-1 disclosures were provided showing ecosystem dependence or customer-to-customer value creation, so network effects cannot be supported here.
Relative to peers with clear marketplace or platform scale, CMND does not appear to benefit from self-reinforcing adoption that would protect margins over 5–10 years.
Cost Advantage
The negative ROIC and ROCE indicate CMND is not converting capital into returns efficiently, which is inconsistent with a durable cost advantage versus peers.
Asset turnover of 0 in the supplied metrics suggests either extremely weak operating efficiency or data limitations, but in either case there is no evidence of a structural unit-cost edge.
No filing evidence was provided for proprietary sourcing, scale purchasing, or lower-cost production, so there is no support for a persistent cost advantage.
Compared with peers that can underprice rivals while preserving margins, CMND does not currently show the economics of a structurally advantaged cost position.
Efficient Scale
The provided information does not show a constrained market structure, and there is no evidence that CMND serves a niche where one or two players can profitably dominate.
Negative returns suggest the company is not capturing scarcity rents from limited local or regulatory scale, which weakens any efficient-scale argument versus peers.
No tier-1 evidence was provided for exclusive licenses, infrastructure bottlenecks, or capacity constraints that would limit competitive entry.
Relative to peers with protected regional franchises or network infrastructure, CMND does not appear to operate at a scale where market size alone deters entry or sustains pricing power.
Overall Score
CMND’s moat appears weak versus peers because the supplied metrics show deeply negative capital returns and no evidence of protected intangibles, switching costs, network effects, cost advantage, or efficient scale; based on the available tier-1 evidence, the business does not currently demonstrate durable structural pricing power or retention over a 5–10 year horizon.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Clearmind Medicine Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
